A Study to Investigate the Biological Effects of AZD9833 in Women With ER-positive, HER2 Negative Primary Breast Cancer
Status:
Recruiting
Trial end date:
2023-01-23
Target enrollment:
Participant gender:
Summary
This is a randomised, open-label, parallel-group, pre-surgical study aimed to investigate the
biological effects, safety, tolerability, and pharmacokinetics (PK) of different doses of
oral AZD9833 in post-menopausal (and potentially pre-menopausal)women with primary breast
cancer.